Growing incidence of product recalls, allegations of spurious drugs and issues related to expired stock in both the international and domestic markets create a cause for concern. The seizure of large quantities of expired drugs being sold under altered labels in early 2010 has raised doubts on the credibility of the industry and the regulatory control on the supply chain.